Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

March 9, 2018

Study Completion Date

March 9, 2018

Conditions
Acne Vulgaris
Interventions
DRUG

dapsone gel

Dapsone (ACZONE) 7.5% gel topically once daily.

Trial Locations (20)

10155

Skin Specialty Dermatology, New York

17033

Department of Dermatology, UPCII, Hershey

19008

KGL Skin Study Center, Broomall

27106

Health Sciences/Department of Dermatology, Winston-Salem

33137

Baumann Cosmetic and Research Institute, Miami Beach

33180

Center for Clinical and Cosmetic Research, Aventura

35233

Kirklin Clinic, Birmingham

40217

Dermresearch, PLLC, Louisville

48059

Hamzavi Dermatology, Fort Gratiot

63104

Saint Louis University Dermatology, St Louis

68144

Skin Specialists, PC, Omaha

76011

Arlington Research Center, Inc., Arlington

77030

University of Texas Medical School at Houston, Houston

78660

Austin Institute for Clinical Research, Inc., Pflugerville

78759

DermResearch, LLC, Austin

91324

Quest Dermatology Research, Northridge

92701

Southern California Dermatology, Santa Ana

94538

Center for Dermatology Clinical Research, Fremont

95401

Redwood Family Dermatology, Santa Rosa

99202

Premier Clinical Research, Spokane

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Almirall, S.A.

INDUSTRY